

## Supplementary Data

---

# Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment

Niklas Mattsson<sup>a,\*</sup>, Erik Portelius<sup>a</sup>, Sindre Rolstad<sup>a</sup>, Mikael Gustavsson<sup>a</sup>, Ulf Andreasson<sup>a</sup>, Mats Stridsberg<sup>b</sup>, Anders Wallin<sup>a</sup>, Kaj Blennow<sup>a</sup> and Henrik Zetterberg<sup>a</sup>

<sup>a</sup>*Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden*


<sup>b</sup>*Department of Medical Sciences, Uppsala University, Uppsala, Sweden*

Handling Associate Editor: Lucilla Parnetti

Accepted 28 February 2012

---

\*Correspondence to: Niklas Mattsson, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, 431 80 Mölndal, Sweden. Tel.: +46 (0)706 393851; E-mail: niklas.mattsson@neuro.gu.se.



Supplementary Figure 1. CSF A $\beta$  isoforms determined by IP-MS in SMCI and MCI-AD patients. Each panel contains data for measurements at baseline, two year follow-up and four year follow-up. Comparisons were done for baseline levels in SMCI versus MCI-AD (using the Mann-Whitney U test) and over-time within the groups (using the Friedman test).